Journal article icon

Journal article

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.

Abstract:

Breast cancer is a heterogeneous disease. Predictive molecular markers are crucial in patient management, but the only recommended predictive biomarkers are estrogen and progesterone receptors and HER2. There are many new targeted therapies, and although the target pathway expression is readily analyzed on conventional pathology, the dynamic response cannot be assessed and pathway expression is no guarantee it has a major driver role, even if mutated. Selecting therapies requires considering ...

Expand abstract

Actions


Access Document


Authors


Expand authors...
Journal:
Journal of the National Cancer Institute. Monographs
Volume:
2011
Issue:
43
Pages:
67-70
Publication date:
2011-01-01
DOI:
EISSN:
1745-6614
ISSN:
1052-6773
URN:
uuid:36cf50ae-608a-4b11-a343-753aae5fe476
Source identifiers:
245927
Local pid:
pubs:245927

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP